Medicinova INC 10-Q quarterly reports

MediciNova, Inc. filed its Q1 2026 10-Q report, detailing financial performance, ongoing clinical trials for MN-166 and MN-001, and strategic financing agreements.

MediciNova, Inc. reported increased net losses for Q3 and the nine months ended September 30, 2025, while securing a new $30 million standby equity purchase agreement to bolster liquidity.

MediciNova, a biopharmaceutical company, reported a wider net loss in Q2 2025 due to increased research and development expenses, while securing a new equity purchase agreement for future funding.

MediciNova, Inc. announces its financial results for the first quarter of 2025, highlighting its ongoing commitment to developing MN-166 and MN-001 for neurological and fibrotic disorders.

MediciNova's Q3 2024 report shows a net loss of $2.85 million, with increased research and development expenses and no revenue, while maintaining a cash balance of $42.3 million.

MediciNova's second quarter 2024 results show a net loss of $2.6 million, with a focus on advancing clinical development programs.

MediciNova, a biopharmaceutical company, announced its first quarter 2024 financial results, highlighting ongoing research and development efforts for its key drug candidates.